DESCRIPTION (provided by applicant): Diabetes increases the risk of severe infections, including periodontitis. Maintenance of homeostasis and tissue health of the periodontium is complicated by overgrowth of specific pathogens. The innate immune response prevents invasion and limits the complexity of the infection. When disease occurs as a complication of systemic disease as in diabetes, tissue damage results from the host response (phagocyte mediated tissue injury), which provides a microenvironment that favors bacterial growth and the chronicity of the lesion. Dysregulated inflammatory/immune reactions have been implicated in the pathogenesis of the complications of diabetes, particularly periodontitis and cardiovascular diseases. Tissues exposed to the external environment and significant bacteria load, such as the periodontium, are at increased risk. The return of inflamed tissues to health and homeostasis is mediated by endogenous agonists that promote resolution of inflammation. The cellular and molecular mechanisms responsible for the resolution of periodontal inflammation are beginning to be mapped. These same proresolution agonists enhance host cell mediated antibacterial activity. Precursor fatty acid substrates from cells (arachidonic acid) and dietary sources (omega-3 fatty acids) yield lipid mediators (lipoxins and resolvins, respectively) that counter-regulate pro-inflammatory signals. Systematic temporal study of periodontal infection and resolution in tissues of people with diabetes is of paramount importance in the treatment of bacterially initiated periodontal disease. The goal of this competing renewal R01 proposal is to determine the impact of infection in resolution circuits of inflammation in people with diabetes. Our novel hypothesis is that restoration of resolution pathways by exogenous administration of resolving molecules will resolve periodontal inflammation and restore homeostasis modifying the composition of the microflora. In this proposal, we will investigate the mechanism of action of phagocyte interactions in the periodontium invoking innate antimicrobial activity and enhanced clearance of pathogens in people with diabetes.
National Institute of Dental and Craniofacial Research
CFDA Code
121
DUNS Number
062190616
UEI
MZ9DFVC2J1B7
Project Start Date
01-April-2005
Project End Date
30-June-2015
Budget Start Date
14-February-2011
Budget End Date
30-June-2011
Project Funding Information for 2010
Total Funding
$549,114
Direct Costs
$299,949
Indirect Costs
$249,165
Year
Funding IC
FY Total Cost by IC
2010
National Institute of Dental and Craniofacial Research
$549,114
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R01DE015566-07
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01DE015566-07
Patents
No Patents information available for 7R01DE015566-07
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01DE015566-07
Clinical Studies
No Clinical Studies information available for 7R01DE015566-07
News and More
Related News Releases
No news release information available for 7R01DE015566-07
History
No Historical information available for 7R01DE015566-07
Similar Projects
No Similar Projects information available for 7R01DE015566-07